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Abstract
Background: The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3
and 6 months. Reports about the application of carmustine (BCNU), one of the standard chemotherapeutic drugs
in the treatment of newly diagnosed glioblastoma, in the recurrent situation are rare.
Methods: We performed a retrospective analysis of 35 patients with recurrent or progressive glioblastoma treated
with 80 mg/m
2 BCNU on days 1 on 3 intravenously at our department for efficacy, toxicity and prognostic factors.
Progression free survival and overall survival were estimated by the Kaplan-Meier method. The influence of age,
Karnofsky performance status (KPS), tumor burden, pretreatment with temozolomide (TMZ), type of surgery for
initial diagnosis and number of previous relapses on outcome was analyzed in a proportional hazards regression
model.
Results: The median age of the group was 53 years, median KPS was 70. Median progression free survival was 11
weeks (95% confidence interval [CI]: 8-15), median overall survival 22 weeks (95% CI: 18-27). The rate of adverse
events, especially hematological toxicity, is relatively high, and in 3 patients treatment had to be terminated due to
adverse events (one pulmonary embolism, one pulmonary fibrosis, and one severe bone marrow suppression). No
influence of age, KPS, tumor burden, pre-treatment with TMZ and number of previous relapses on outcome could
be demonstrated, while gross total resection prior to recurrence showed a borderline statistically significant
negative impact on PFS and OS. These data compare well with historical survival figures. However prospective
randomized studies are needed to evaluate BCNU efficacy against newer drugs like bevacizumab or the intensified
temozolomide regime (one week on/one week off).
Conclusion: In summary, BCNU treatment appears to be a valuable therapeutic option for recurrent glioblastomas,
where no other validated radio- and/or chemotherapy are available.
Background
Despite optimal treatment of patients with newly diag-
nosed glioblastoma multiforme by surgery, irradiation
and chemotherapy, median survival is still only 14.6
months [1], and recurrent glioblastoma confers a dismal
prognosis with a 6-months progression free survival
(6M-PFS) rate of 15% to 21% and a median survival of
2 5w e e k s[ 2 ] .T h i su n f a v o r a b l ep r o g n o s i si sm a i n l yd u e
to the high propensity for tumor recurrence that inevita-
bly occurs after a median survival time of 32 to 36
weeks [3,4]. The optimal treatment strategy in recurrent
glioblastoma is ill-defined, and different chemotherapeu-
tic regimes are used due to limited therapeutic options.
Carmustine (BCNU) is one of the few chemotherapeutic
drugs that are FDA approved for treatment of GBM
according to positive experiences in the sixties with
reported response rates of up to 30%. These report rates
were mainly based on clinical criteria and might be
overestimated. Few data exist about the efficacy of
BCNU in patients with recurrent glioblastoma. Brandes
[5] reported about 40 patients with recurrent glioblas-
toma treated with BCNU and found a six months pro-
gression free survival of 17.5% and a median time to
progression of 13.3 weeks. However, all of these patients
were chemo naive, and pretreatment consisted solely of
surgery and irradiation. Since the study of Stupp [1] in
2005, the standard treatment for patients with primary
glioblastoma includes a concomitant and adjuvant che-
motherapy with temozolomide. As the cytotoxic effect
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effect of the DNA, the considered resistance mechan-
isms of cancer cells could be equal effective for both
drugs. In the case of temozolomide the temozolomide
induced methyl adducts at the O
6-guanine in DNA is
repaired by the O
6-methylguanine-DNA methyltransfer-
ase (MGMT) cytoprotective repair protein [6], and
MGMT is also discussed as the main resistance
mechanism against nitrosoureas [7]. However, no study
investigated the impact of pretreatment with temozolo-
mide on the efficacy of BCNU in the treatment of recur-
rent glioblastoma. Additionally the influence of tumor
burden, age and Karnofsky performance status (KPS)
and number of previous relapses on BCNU efficacy was
also examined.
Therefore, this study was performed to obtain
further data about the efficacy and toxicity of BCNU
in recurrent glioblastoma that could serve as a bench-
mark for newer drugs, and to identify possible prog-
nostic factors.
Methods
Patients’ selection
We performed a retrospective review of the MS
ACCESS database of our department for all patients
with high-grade gliomas who received chemotherapy
with BCNU between 12/2003 and 05/2008, and identi-
fied 93 patients. The patients’ records as well as histolo-
gical and radiological examinations were re-examined,
and patients with a histologically proven glioblastoma,
and radiological evidence of recurrent or progressive
disease according to the Mac Donald criteria [8] or clin-
ical progression were included into the study. A radiolo-
gically recurrent disease was defined as any new
contrast enhancing area after complete resection of all
contrast-enhancing tumor areas. A radiologically proven
progressive disease was defined as any increase of con-
trast enhancing tumor area over 25% or an additional
contrast enhancing area. Clinical progression was
defined as the occurrence of significant neurological
deterioration (e.g. disabling hemiparesis, aphasia, and
deterioration of the general condition). Patients with a
malignant transformation of a previous low-grade dis-
ease into a glioblastoma were also included. Patients in
whom BCNU treatment of recurrent glioblastoma had
been initiated before 2003 were excluded. According to
these criteria, 35 of these 93 patients were eligible for
this study. The study was approved by the local ethic
committee.
Treatment
The treatment schedule consisted of intravenous appli-
cation of 80 mg/m
2 B C N Uo nd a y s1t o3 .T h et r e a t -
ment cycle was repeated every 8 weeks for a maximum
of 6 cycles. Patients were evaluated weekly for hemato-
logic, renal, and hepatic toxicity. Treatment was termi-
nated in the presence of either a neuroradiological or
clinical progression or inacceptable toxicity (white blood
cell count < 500 cells/μl; thrombocyte count < 10.000
cells/μl).
Response evaluation
Patients underwent routinely neuroradiological and clin-
ical evaluation for tumor response every 8 weeks or ear-
lier, when clinical deterioration occurred. Radiological
response was assessed according to the Mac Donald cri-
teria [8]. A complete response was defined as the disap-
pearance of all enhanced tumor, a partial response as a
50% or greater reduction in the largest cross-sectional
t u m o ra r e aa n dap r o g r e s s i v ed i s e a s ea sa2 5 %i n c r e a s e
in the size of the enhancing tumor or appearance of a
new lesion. According to Norden et al. [9] we defined
minimal response as a 25% to 49% reduction in the lar-
gest cross-sectional tumor area. All other situations
were defined as radiologically stable disease. A clinical
progression of the disease was defined as the occurrence
of significant neurological deterioration (e.g. disabling
hemiparesis, aphasia, and deterioration of the general
condition). In case of a clinical or radiological progres-
sion BCNU treatment was terminated. In all other cases
BCNU treatment was repeated up to a maximum of 6
cycles.
Evaluation of tumor burden
The largest cross-sectional tumor area at start of the
BCNU therapy was defined as the tumor burden and
was the result of the multiplication of the largest cross-
sectional diameters.
Study endpoints
Study endpoints included evaluation of progression free
and overall survival. Progression free survival was
defined as the interval from start of BCNU treatment to
radiological or clinical progression or death, whichever
occurred first. Overall survival was defined as the time
span from start of BCNU until death from any cause.
Patients’ general practitioners were contacted between
May and September 2008 to obtain the most recent fol-
low-up information.
Statistical methods
Progression free and overall survival were estimated by
the Kaplan-Meier method, censoring observations at the
time of last follow-up if the respective event was not
observed. Median follow-up was derived from the esti-
mated censoring distribution. Prognostic factors (age,
KPS, tumor burden, gross total resection, pretreatment
with TMZ, number of previous relapses) were all fitted
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model, both as continuous and dichotomised predictors.
Two-sided 95% confidence intervals were used and sta-
tistical significance defined as p < 0.05 based on two-
sided tests.
Results
Patients’ characteristics
Thirty-five patients were included into the study. 34
patients had a histologically proven GBM, in one patient
diagnosis of GBM was confirmed in the combination of
histopathological, neuroradiological and clinical findings.
There were 21 (60%) men and 14 (40%) women with a
median age of 53 years (range: 27 to 77 years). 26
patients (74%) were older than 45 years and median
KPS at start of BCNU treatment was 70 (range: 40-90),
37% of the patients had a KPS below 70.
Tumor involved one lobe in 22 patients (12 temporal,
5 frontal, 4 parietal, 1 central), two or more lobes in 10
patients (6 parieto-temporal, 2 fronto-temporal, 1 tem-
poro-parietal, 1 fronto-temporo-parietal) and was multi-
focal in 3 patients. The operative procedure at time of
first diagnosis of GBM was a gross total resection in 15,
a partial resection in 4 and a stereotactic biopsy in 16
patients. 31 (89%) patients received postoperative radio-
therapy to limited fields and 24 (69%) additionally an
adjuvant and concomitant chemotherapy with temozolo-
mide. In 30 patients BCNU therapy was initiated after
the first relapse, in four patients after the second relapse
(first relapse was treated in 2 patients with stereotactical
application of an immunotoxin, in 1 patients with an
alternative chemotherapeutic regime (cilengitide) and in
one patients a circumscribed tumor progress was irra-
diated with LINAC) and in one patient after the fourth
relapse (first relapse treated with LINAC, second and
third relapse operated). Median time span from initial
diagnosis to start of BCNU therapy was 38 weeks
(range: 11-189 weeks). For further details see also table
1 and 2.
Toxicity
62 cycles of BCNU were administered, ranging from 1
to 4 cycles, with a mean of 1.8 cycles per patient. Bone
marrow toxicity, coagulopathies, pulmonal and infec-
tious complications were evaluated according to the
c o m m o nt o x i c i t yc r i t e r i af o ra d v e r s ee v e n t sV 3 . 0 .I n
summary 7 patients developed one or more adverse
events during BCNU therapy. 4 patients developed
thrombocytopenia grade 3 or 4, 5 patients developed
leucopenia grade 3 or 4 and 1 patient developed an ane-
mia grade 3. Two patients developed infection grade 3
or 4 and one patients a thromboembolic event grade 4
associated with pulmonary embolism. One patient
experienced an interstitial lung fibrosis grade 3 after the
administration of the third cycle BCNU. All patients
with bone marrow toxicities grade III or IV have been
pretreated with temozolomide, have been administered
two or more cycles of BCNU and have had a stereotac-
tic biopsy. In three patients BCNU treatment was termi-
nated due to adverse events (one patient with
pulmonary embolism, one patient with pulmonary fibro-
sis, one patient with extensive myelotoxicity).
Response rates
In two patients a partial response and in 19 patients a
stable disease was observed. We found no patients with
a minimal or complete response. 11 patients showed a
progressive disease after application of the first cycle. In
three patients evaluation of radiological response was
not possible.
Progression free and overall survival
Of 35 patients, 29 progressed within the follow-up per-
iod, 5 were alive and progression-free, and one patient
died 28 weeks after initiation of BCNU with no data on
progression available (omitted from analysis of progres-
sion free survival). 30 patients died, 5 were alive at the
end of follow-up. Median progression free survival was
11 weeks (95% confidence interval [CI]: 8-15 weeks),
with a 6 months progression free survival rate of 13%
(Figure 1; median follow-up: 30 months). Median overall
survival was 22 weeks (95% CI: 18-27 weeks), 43% sur-
vived for more than 6 months (Figure 2).
In an explorative proportional hazards regression
model for the effects of dichotomized prognostic factors
(age, KPS, tumor burden, gross total resection prior to
recurrence, pre-treatment with TMZ and number of
previous relapses) on progression free survival, only
gross total resection showed a borderline statistically
significant association withah i g h e rr i s ko fr e l a p s e
(hazard ratio of progression 3.11 for gross total resection
compared with partial resection/biopsy; 95% CI 1.02-
9.52; p = 0.047; table 3). The same model was used for
overall survival and also identified only gross total resec-
tion as a statistically significant negative prognostic fac-
tor for survival (hazard ratio of overall survival 3.034 for
complete resection compared with partial resection/
biopsy; 95% CI 1.05-8.7; p = 0.04; table 4).
Discussion
The natural history and optimal treatment of recurrent
glioblastoma is not well-defined due to lack of uniform
definition and criteria for tumor recurrence, institutional
variability in treatment strategy and the heterogeneous
nature of the disease including location of recurrence.
Treatment options for recurrent glioblastoma include
surgical intervention, chemotherapy or irradiation
(stereotactic radiosurgery and brachytherapy). The
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sure, improve neurological status of the patient and pos-
sibly improve efficacy of adjunctive therapy. Additionally
it offers the possibility of BCNU-impregnated wafer
insertion into the resection cavity and in combination
with irinotecan median survival rates of 13.5 months are
reported [10]. Overall, resection may provide a modest
benefit in survival and/or improvement in quality of life
within a subset of patients and should only be consid-
ered in patients with a KPS score > 70 with lesions in
favourable locations [1,11,12].
Stereotactic radiosurgery (SRS) is a treatment option
for small recurrent glioblastoma. Median survival of
patients undergoing single-fraction SRS is around 10
months [13-15] and can be applied as an outpatient
therapy. Brachytherapy has a similar efficacy as SRS,
with a median survival time of 9.1 months [16] and a
3-year survival rate of 15% [17], but only 20-30% of
patients with recurrent glioblastoma meet the morpho-
logical and focal criteria for application of interstitial
brachytherapy.
For these reasons chemotherapy is still the most
common treatment option for recurrent glioblastoma
multiforme [18]. Besides the use of temozolomide, car-
boplatin, procarbazine and imatinib mesylate, which
are hypothesized to reduce the patient’sr i s ko fd e a t h
by approximately 15% [19], are the most widely used
drugs. Wong et al. [2] summarized the results of
Table 1 Patients’ characteristics
Sex
Male 21 (60%)
Female 14 (40%)
Age, years
Median 53
Range 27-77
< = 45 9 (26%)
> 45 27 (74%)
Tumor burden (product of largest cross-sectional diameters), mm2
Median 736
Range 20-3519
Not measurable n = 8 (23%)
KPS
Median 70
Range 40-90
90 7 (20%)
70-80 15 (43%)
<70 13 (37%)
Time from diagnosis to start of BCNU, weeks
Median 38 weeks
Range 11-189 weeks
Primary therapy
Total resection 15 (43%)
Partial resection 4 (11%)
Biopsy 16 (46%)
Temozolomide 24 (71%)
Radiation 31 (89%)
Number of relapses at start of BCNU therapy
First 30 (86%)
Second 4 (11%)
Third 0 (0%)
Fourth 1 (3%)
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mas and found 6 months progression free survival rate
of 15% for patients with recurrent glioblastomas. Over-
all survival was 30 weeks, however with no differentia-
tion between anaplastic astrocytoma and glioblastoma.
Wick et al. [20] suggested an intensified TMZ scheme
(one week on/one week off) and found 6-months-PFS
of 48% in a patient population with a favourable KPS.
Vredenburgh et al. [21] applied a combined therapy of
bevacizumab and irinotecan in 35 patients and
reported 6-months-PFS of 46% and an overall survival
of 42 weeks.
However, the role of BCNU - one of the few drugs
with proven activity against GBM - in this situation is
poorly defined. Brandes et al. [22] performed the only
phase II trial with BCNU in recurrent glioblastoma and
reported a median time to progression of 13.3 weeks
and 6 months PFS rate of 17.5%.
Our results compare well with the reported 6-months
progression free survival and overall survival rates
reported by Brandes [22] and Wong [2] but more
recently introduced drugs like bevacizumab or intensi-
fied TMZ scheme (one week on/one week off) seems to
further improve 6 months PFS and overall survival.
However, the limited effect of BCNU on PFS in our ser-
ies can in part be explained by the problem of pseudo-
progression in malignant glioma. This phenomenon
describes progressive and enhancing lesions on MRI,
which are not related to tumor progression, but which
are treatment effects [23] and has been originally
described after chemoradiotherapy with temozolomide.
As in 16 patients in our series BCNU therapy was ter-
minated due to a radiographic progress of the disease
without any clinical deterioration it can be assumed that
these changes might be in some cases treatment related
and not a true objective tumor progression. However
pseudoprogression after BCNU therapy has not been
described in the literature to date and therefore we
would suggest to perform a radiological follow-up exam-
ination in patients with radiological signs of tumor pro-
gression to rule out pseudoprogression and a
misleadingly termination of therapy.
It has to be considered that our study population was
very heterogeneous with a high variation of tumor bur-
den and a high proportion of patients older than 45
years, who had already received various therapeutic
modalities and were not only treated for the first but
also for a second or fourth relapse of the disease.
Figure 1 Progression free survival. Kaplan-Meier curve showing progression free survival for recurrent glioblastoma multiforme after BCNU
chemotherapy.
Table 2 Treatment modalities in the relapse situation
First relapse Second relapse Third relapse Fourth relapse
BCNU 30 4 0 1
Resection 0 1 1 0
LINAC radiosurgery 2 0 0 0
Local immunotoxin administration 2 0 0 0
Alternative chemotherapy
(cilengitide)
1000
Reithmeier et al. BMC Cancer 2010, 10:30
http://www.biomedcentral.com/1471-2407/10/30
Page 5 of 8Therefore, we investigated if age, KPS, tumor burden,
number of previous relapses or pre-treatment with TMZ
had any impact of patient’s PFS or overall survival.
As TMZ and BCNU are counteracted via the same
resistance mechanism, we hypothesized that pre-treat-
ment with TMZ could have led to a resistance against
alkylating agents reducing the efficacy of BCNU. We
found no statistically significant impact of TMZ pre-
treatment on PFS or overall survival, so that BCNU is
still a therapeutic option for patients progressive under
TMZ as the role of alkylating agents in the development
of chemotherapeutic alkylating drug resistance remains
still unclear [24]. However, one limitation of this study
is the missing information about the status of MGMT
promoter methylation. Molecular studies have demon-
strated that the benefit from alklyating chemotherapy is
mainly observed in patients with a methylated MGMT
gene promoter, and are thus unable to repair some of
the chemotherapy-induced DNA damage [25,26] and
MGMT expressing tumor cells are 4- to 10-fold more
resistant to BCNU, temozolomide and related com-
pounds [27,28]. Molecular and epigenetic characteriza-
tion of gliomas is essential in future glioma therapy to
develop individual therapeutic strategies and to over-
come the MGMT mediated chemoresistance. One con-
cept is to irreversibly inactivate MGMT through
administration of O
6-Benzylguanine, a compound that
reacts with MGMT by covalent transfer of the benzyl
group to the active site-cysteine and renders by this way
the tumor cells 2- to 14-fold more sensitive to alkylating
agents in vitro and in vivo settings [29] and phase II
trials to prove the potential benefit of a combination of
O
6-Benzylguanine with temozolomide or BCNU are cur-
rently under way [24].
The tumor burden at the beginning of BCNU ther-
a p yh a dn oi n f l u e n c eo nP F So ro v e r a l ls u r v i v a l .T h i s
is in line with the level II recommendations for the
surgical management of newly diagnosed glioblasto-
mas, that recommend that only maximal cytoreductive
surgery (>98% of tumor) correlates with a significant
effect on survival [30-32]. Therefore, reoperation for
recurrent GBM should onlyb ec o n s i d e r e dw h e na
maximally safe and maximally cytoreductive surgery is
possible.
Brandes [5], who also investigated the influence of age,
KPS and response to chemotherapy on prognosis, found
Table 3 Determinants of progression-free survival after BCNU treatment of recurrent glioblastoma (n = 34, 30 events)
Hazard ratio* 95% confidence interval p-value
Age (years) ≤ 53 vs. > 53 (the median) 1.12 0.41-2.98 0.844
Tumor size (mm
2) ≤ 736 vs. > 736 (the median) 0.46 0.15-1.42 0.177
not measurable vs. > 736 0.45 0.16-1.28 0.135
Karnofsky performance score ≤ 70 vs. 80 or 90 0.50 0.20-1.26 0.143
Surgery Complete resection vs. biopsy/partial resection 3.11 1.02-9.52 0.047
Pre-treatment with temozolomide yes vs. no 1.30 0.43-3.91 0.641
Previous relapses 1 vs. more than 1 0.48 0.14-1.61 0.232
* A hazard ratio <1 (>1) indicates an effect in favor of the first (the second) group in terms of progression-free survival.
Figure 2 Overall survival. Kaplan-Meier curve showing overall survival for recurrent glioblastoma multiforme after BCNU chemotherapy.
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motherapy remained an independent prognostic factor
for time to progression.
In summary, we could not identify an influence of age,
KPS, tumor burden, pre-treatment with TMZ or num-
ber of previous relapses on PFS or OS in our patient
population. The data do suggest a negative impact of a
gross total resection prior to recurrence in terms of PFS
and OS, This might be due to a negative selection of
patients with extensive tumor growth after initial com-
plete resection who are not amenable for reoperation.
Conclusion
Based on these findings we would recommend for
patients with recurrent glioblastoma, who are not
enrolled into clinical studies, to start with the intensified
temozolomide scheme due to less toxic effects and
superior progression free survival figures compared to
BCNU. However, as we found no objective prognostic
factors of BCNU efficacy it represents a valuable thera-
peutic option after a further progression when no other
validated treatment modalities are available and the high
rate of toxicity, especially after pre-treamtent with temo-
zolomide has to be considered. Prospective and rando-
mized studies are needed to compare the efficacy of
nitroso-ureas against newer drugs like bevacizumab to
prove their therapeutic superiority in the recidive
situation.
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